Yahoo · Oct 30, 2026
Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”
Key TakeawaysAgios Pharmaceuticals shares fell [19%] after the FDA moved its mitapivat decision in sickle cell disease to Feb. 1, 2027.
AG
NASDAQ · AGIO
Agios Pharmaceuticals, Inc.
Healthcare · Biotechnology
$31.20
Up+$0.18 (+0.58%)
Updated Nov 4, 2026, 11:02 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.77B
- P/E ratio
- -4.27
- Dividend yield
- 0.00%
- 52-week range
- $22.24 – $46.00
- Volume
- 685.4K
- Avg. volume
- 1.17M
Price performance · AGIO
AGIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
AGIO closed at $31.20 after 21 trading sessions, down 1.64% for the selected period.
- Last close
- $31.20
- Period change
- -1.64%
- Period low
- $29.95
- Period high
- $38.12
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $30.20 | $31.635 | $30.06 | $31.20 | 685.4K |
| Nov 2, 2026 | $30.95 | $31.42 | $29.825 | $29.95 | 1.91M |
| Oct 30, 2026 | $31.43 | $33.00 | $29.80 | $30.55 | 3.09M |
| Oct 29, 2026 | $38.23 | $38.69 | $36.76 | $37.23 | 984.41K |
| Oct 28, 2026 | $37.46 | $38.44 | $36.86 | $38.12 | 1.4M |
| Oct 27, 2026 | $36.59 | $38.07 | $36.30 | $38.03 | 739.09K |
| Oct 26, 2026 | $37.32 | $38.13 | $36.63 | $36.85 | 838.54K |
| Oct 23, 2026 | $36.93 | $37.32 | $36.10 | $37.00 | 920.05K |
| Oct 22, 2026 | $37.22 | $37.74 | $36.35 | $37.19 | 931.1K |
| Oct 21, 2026 | $36.62 | $37.585 | $36.455 | $37.18 | 849.89K |
| Oct 20, 2026 | $35.04 | $37.00 | $35.02 | $36.64 | 1.52M |
| Oct 19, 2026 | $31.61 | $35.025 | $31.61 | $34.90 | 1.97M |
| Oct 16, 2026 | $32.35 | $32.515 | $31.16 | $31.32 | 952.68K |
| Oct 15, 2026 | $31.70 | $32.84 | $31.35 | $32.32 | 2.05M |
| Oct 14, 2026 | $30.07 | $31.11 | $29.67 | $30.97 | 930.9K |
| Oct 13, 2026 | $30.60 | $30.99 | $30.095 | $30.21 | 1.17M |
| Oct 12, 2026 | $31.84 | $32.22 | $30.69 | $30.82 | 647.85K |
| Oct 9, 2026 | $31.85 | $32.15 | $31.52 | $31.81 | 835.68K |
| Oct 8, 2026 | $31.46 | $32.315 | $31.16 | $31.92 | 2.08M |
| Oct 7, 2026 | $31.37 | $32.27 | $31.0701 | $31.79 | 1.67M |
| Oct 6, 2026 | $31.49 | $32.03 | $30.79 | $31.72 | 1.28M |
Latest AGIO news
The latest Smart Investors Daily articles mentioning AGIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AGIO research
Overview
Company profile and research snapshot.
Company profile
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 7, 2026 | JP Morgan | Neutral | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 30, 2026
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. I rate AGIO stock as Buy. Read my update.
Yahoo · Oct 30, 2026
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extensionMitapivat sNDA was submitted under the FDA’s accelerated approval pathway and granted Priority Review, with an original PDUFA goal date of November 1, 2026Agios will continue its labeling discussions with the FDA as part of the ongoi
Benzinga · Oct 30, 2026
Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major amendment to the mitapivat
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
